NRx Pharmaceuticals, Inc.
General ticker "NRXP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $44.3M (TTM average)
NRx Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 21.7%.
Estimated limits based on current volatility of 2.6%: low 1.78$, high 1.89$
Factors to consider:
- Earnings expected soon, date: 2026-03-13 bmo
- Total employees count: 3 as of 2017
- Top business risk factors: Insufficient funding, Regulatory and compliance, Limited operating history, Dependence on product success, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.81$, 3.40$]
- 2025-12-31 to 2026-12-31 estimated range: [0.74$, 3.09$]
Financial Metrics affecting the NRXP estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -63.33 <= 0.01
- Positive: Investing cash flow per share per price, % of 0 > -0.63
- Positive: Inventory ratio change, % of 0 <= 0
Short-term NRXP quotes
Long-term NRXP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $44.34MM | $27.84MM | $19.70MM |
| Operating Income | $-44.34MM | $-27.84MM | $-19.70MM |
| Non-Operating Income | $4.58MM | $-2.31MM | $-5.42MM |
| Interest Expense | $0.00MM | $0.12MM | $1.08MM |
| R&D Expense | $17.03MM | $13.37MM | $6.20MM |
| Income(Loss) | $-39.75MM | $-30.15MM | $-25.13MM |
| Profit(Loss)* | $-39.75MM | $-30.15MM | $-25.13MM |
| Stockholders Equity | $7.41MM | $-11.73MM | $-23.22MM |
| Assets | $25.82MM | $7.32MM | $3.65MM |
| Operating Cash Flow | $-39.76MM | $-21.66MM | $-10.64MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.01MM | $-0.00MM | $0.00MM |
| Financing Cash Flow | $32.21MM | $6.20MM | $7.49MM |
| Earnings Per Share** | $-0.60 | $-3.98 | $-2.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.